Navigation Links
Affitech Acquires Pharmexa's Diabody Technology

OSLO, Norway, October 28 /PRNewswire/ -- Affitech AS, the human therapeutic antibody company, today announced that it had acquired the full rights to the innovative diabody technology originally owned by Pharmexa A/S, a leading Danish immunotherapeutic and vaccine company. Also known as bi-specific single chain antibodies, diabodies are recombinant antibody-like proteins whose unique attributes make them attractive candidates for a variety of therapeutic applications. The acquisition follows an exclusive license of the diabody IP that Affitech obtained in 2007 from Pharmexa to carry out certain non-clinical GLP compliant studies, as well as sub-licensing arrangements with third parties.

Affitech CEO Martin Welschof commented:

"This is a key strategic move for Affitech AS, since this diabody technology complements our existing antibody discovery platform perfectly. We are delighted to have this technology under our total ownership, which will benefit both our proprietary programs and our collaborations with pharma and biotech companies. In addition we will continue to seek actively sublicensing arrangements with third parties."

Editors notes

Affitech AS is a privately held human therapeutic antibody discovery and development company with headquarters and R&D facilities in Oslo, Norway and its US subsidiary in the San Francisco Bay Area. The Company's current disease focus is oncology and it utilizes two discrete but unique approaches for the discovery of fully human antibodies - (i) Molecule Based Antibody Discovery, and (ii) Cell Based Antibody Discovery. Molecule Based Antibody Discovery involves proprietary PhagemidScreeN and AffiScreeN(TM) technologies and uses validated targets for discovery purpose. Cell Based Antibody Discovery utilizes CBAS(TM) technology, which is a "reverse-screening" approach for discovering antibodies and their cognate targets from disease-specific cells. CBAS(TM) is also applicable to discovering antibodies against targets when present in their naturally folded forms on cell surface. Some of the Company's proprietary product candidates currently in research and development were generated by CBAS(TM). Affitech has concluded deals with commercial organizations such as Omeros, Roche, Peregrine, XOMA, NatImmune, Viventia, Dyax, Micromet, Pharmexa and others. Affitech offers collaborators a flexible business model and a competitive price structure with low royalty stacking. Further information at

Contacts for Affitech:

Affitech (Norway):

Dr. Martin Welschof,

Chief Executive Officer,

+47-22-95-87-58, .

Affitech (USA):

Dr. Rathin C. Das President,

+1-925-935-9803, .

SOURCE Affitech AS
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Affitech and Omeros Enter Into Antibody Discovery and Development Agreement
2. Affitech Appoints Dr. Keith McCullagh as Chairman
3. Affitech Announces Second Milestone in Roche Antibody Discovery Collaboration
4. Clinical Data Acquires Epidauros Biotechnologie AG, Significantly Enhancing Proprietary Genetic Biomarker Portfolio
5. Neogen Acquires Kane Enterprises
6. OncoVista, Inc. Closes on $6.8 Million Financing and Acquires Control of a Public Shell Company
7. Thermo Fisher Scientific Acquires Instrument Sales Business of Davis Inotek
8. United BioSource Acquires Interest in Leading Adaptive Design Technology Service Provider
9. NSF International Acquires David Begg Associates
10. United BioSource Acquires Caro Research, Leader in Simulation Modeling
11. Respironics Acquires Apollo Light Systems, Inc., Expands into Circadian Rhythm Device-Based Therapy Market
Post Your Comments:
(Date:11/27/2015)... 2015 /PRNewswire/--  Mallinckrodt plc (NYSE: MNK ), ... has closed the sale of its global contrast media ... Euronext) in a transaction valued at approximately $270 million. ... a total of approximately 1,000 employees spread across the ... Louis area. This entire workforce and the ...
(Date:11/27/2015)... PUNE, India , November 27, 2015 ... --> Growing popularity of companion ... emerging in cancer biomarkers market with pharmaceutical ... develop in-demand companion diagnostic tests. ... --> Complete report on global ...
(Date:11/26/2015)... November 26, 2015 --> ... specializing in imaging technologies, announced today that it has received ... of the Horizon 2020 European Union Framework Programme for Research ... clinical trial in breast cancer. , --> ... --> --> The study aims ...
(Date:11/25/2015)... 25, 2015  PharmAthene, Inc. (NYSE MKT: PIP) announced ... stockholder rights plan (Rights Plan) in an effort to ... (NOLs) under Section 382 of the Internal Revenue Code ... PharmAthene,s use of its NOLs could be substantially limited ... in Section 382 of the Code. In general, an ...
Breaking Biology Technology:
(Date:11/2/2015)... Calif. , Nov. 2, 2015  SRI International ... million to provide preclinical development services to the National ... contract, SRI will provide scientific expertise, modern testing and ... variety of preclinical pharmacology and toxicology studies to evaluate ... --> The PREVENT Cancer Drug Development Program ...
(Date:10/29/2015)... Calif. , Oct. 29, 2015  The J. ... new report titled, "DNA Synthesis and Biosecurity: Lessons Learned ... the Department of Health and Human Services guidance for ... in 2010. --> ... it also has the potential to pose unique biosecurity ...
(Date:10/29/2015)... ARBOR, Mich. , Oct. 29, 2015 /PRNewswire/ ... Eurofins Genomics for U.S. distribution of its DNA ... DNA-seq kit and Rubicon,s new ThruPLEX Plasma-seq kit. ... to enable the preparation of NGS libraries for ... plasma for diagnostic and prognostic applications in cancer ...
Breaking Biology News(10 mins):